As a leader in multiplex diagnostics at the Point of Care, QuantuMDx is committed to sharing ideas and being actively engaged to turn challenges into opportunities. Access here our news, blogs and events.
QuantuMDx are delighted to have been awarded the Outstanding Achievement Award sponsored by Abacus at the 2024 Medilink Healthcare Business Awards. This award was for the Q-POC point of care PCR platform. It was a great evening with some truly inspiring stories....
QMDx attended the Great North Research Conference recently. This was the first conference organised by NIHR to bring together academics and commercial companies within the North of England, to celebrate their achievements and showcase their expertise to allow for...
We are delighted to share another achievement for QuantuMDx, and the North-East, within the molecular diagnostics space. On November 27th, 2023, QuantuMDx was invited to participate in the Global Investment Summit 2023 at Hampton Court Palace. This exclusive event...
NEWCASTLE UPON TYNE, UK 13 December, 2022. QuantuMDx Group Limited (“QuantuMDx”), today announces that its Q-POC™ SARS-CoV-2, Flu A/B & RSV Assay, has been approved for sale in the UK under The Medical Devices (Coronavirus Test Device Approvals) (Amendment)...
Agreement will initially cover the UK and France with potential to expand to other European countries and worldwide NEWCASTLE UPON TYNE, UK, 2 November 2022. QuantuMDx Group Limited (“QuantuMDx”), a UK-based developer of transformational Point of Care molecular...
The agreement sets a roadmap for the commercialisation of Q-POC™ and its assays in China The two companies will collaborate to accelerate the development of new assays on the Q-POC™ platform Offers potential for component sourcing and manufacturing optimisation...
Diagnosing, treating and managing respiratory infections NEWCASTLE UPON TYNE, UK, 5 July 2022. QuantuMDx Group Limited (“QuantuMDx”) will be offering insights and advice on tackling respiratory infections in the wake of the pandemic during a webinar later this month....
NEWCASTLE UPON TYNE, UK, [17 June 2022. QuantuMDx Group Limited (“QuantuMDx”), a UK-based developer of transformational Point of Care diagnostics, is pleased to announce that Q-POC™ has made the SelectScientists’ Choice Awards shortlist for the Best New Clinical...
NEWCASTLE UPON TYNE, UK, 14 June 2022. QuantuMDx Group Limited (“QuantuMDx”), a UK-based developer of transformational Point-of-Need diagnostics, is pleased to announce that its Co-Founder and former CEO Elaine Warburton OBE, has been recognised as one of the top 50...
NEWCASTLE UPON TYNE, UK, [9] June 2022. QuantuMDx Group Limited (“QuantuMDx”), a UK-based developer of transformational point-of-care diagnostics, is pleased to announce that it has won the Special Recognition Award (Response to Covid-19)] at the Med-Tech Innovation...
New multiplex panel can detect SARS-CoV-2, Flu A, Flu B & RSV at the Point of Care Accurate PCR results delivered in approximately 30 minutes NEWCASTLE UPON TYNE, UK, 26 May 2022. QuantuMDx Group Limited (‘QuantuMDx’ or the ‘Company’), a UK-based...
NEWCASTLE UPON TYNE, UK, [13] May 2022. QuantuMDx Group Limited (“QuantuMDx”), is pleased to announce that it has won the Innovation Award at the Medilink Healthcare Business Awards 2022. The Innovation Award was awarded to the Company’s Q-POC™ platform, recognising...
NEWCASTLE UPON TYNE, UK, 29 APRIL 2022. QuantuMDx Group Limited (“QuantuMDx”), is thrilled to announce the launch of a new website www.quantumdx.com/. Our new website features improved functionalities and easy access to essential information about our solution and our...
NEWCASTLE UPON TYNE, UK, 01 APRIL 2022. QuantuMDx Group Limited (“QuantuMDx”), is pleased to announce that it has won two Bionow Awards 2021, which took place last night, Thursday 31 March 2022. The company was shortlisted for three awards, winning two in total. The...
NEWCASTLE UPON TYNE, UK, 25 MARCH 2022. QuantuMDx Group Limited (“QuantuMDx”), is pleased to announce that it has won the Medical Life Sciences award at the Made in North East Awards 2022. The Made in North East Awards applaud quality products and services that...
NEWCASTLE UPON TYNE, UK, 10 MARCH 2022. QuantuMDx Group Limited (“QuantuMDx”), today announces that its SARS-CoV-2 RT -PCR detection assay, has been approved in the UK under the UK Health Security Agency’s Medical Devices (Coronavirus Test Device Approvals)...
NEWCASTLE UPON TYNE, UK, 24 FEBRUARY 2022. QuantuMDx Group Limited (“QuantuMDx”), is pleased to announce the appointment of Martin Walton as Chief Financial Officer. Martin has over 35 years’ experience working within large global companies with the last 15...
NEWCASTLE UPON TYNE, UK, 22 FEBRUARY 2022. QuantuMDx Group Limited (“QuantuMDx”), today announces that its rapid PCR SARS-CoV-2 test, with the multiplex Q-POC™ platform, has been approved for continued sales in the UK under the UK Health Security Agency’s Medical...
NEWCASTLE UPON TYNE, UK, 26 NOVEMBER 2021. QuantuMDx Group Limited (“QuantuMDx”), today confirms that both its SARS-CoV-2 assays for open PCR platforms and its rapid PCR device, Q-POC™, as well as its future respiratory panel (SARS-CoV-2, Flu A, Flu B and RSV A/B),...
Funds will be used to develop further multiplexing capabilities and menu expansion in collaboration with Sansure, on the Q-POC™ platform Cooperation Agreement to accelerate regional commercialisation of Q-POC™ and its cassettes in China and other South-East Asian...
Providing a rapid, PCR COVID-19 testing solution to the UK film & TV industry NEWCASTLE UPON TYNE, UK, 16 August 2021. QuantuMDx has announced it is partnering with Cignpost Diagnostics, (‘Cignpost’), a leading provider of COVID-19 workplace testing to the...
NEWCASTLE UPON TYNE, UK: QuantuMDx today announces the launch of Q-POC™ - a rapid, PCR point of care diagnostic system. Launching at ECCMID 2021, QuantuMDx’ Q-POC™ system and its first test, a SARS-CoV-2 detection assay, are now CE-IVD marked under the In Vitro...
Diagnostic Goods and Services (Lot 1) Research and Development Goods (Lot 2) NEWCASTLE UPON TYNE, UK, 08 June 2021. QuantuMDx has been successful in both Public Health England (‘PHE’) tenders the Company applied for. QuantuMDx will be included in the Framework...
NEWCASTLE UPON TYNE, UK, 26 May 2021. QuantuMDx has appointed Mirre de Noo, as a Non-Executive Director. Mirre has over 20 years of experience in healthcare, strategy and innovation. As a life sciences and healthcare executive she has a track record of introducing and...
NEWCASTLE UPON TYNE, UK, 24th March 2021. QuantuMDx today announces it has raised £11 million in its latest funding round. Proceeds will be used to complete manufacturing and commercial scale up of Q-POC™, QuantuMDx’s rapid, PCR point of care diagnostic system...
NEWCASTLE UPON TYNE, UK, 13 February 2021. QuantuMDx today welcomed the Prime Minister, Rt Hon Boris Johnson MP, for a tour of its purpose-built HQ in Newcastle upon Tyne. QuantuMDx has developed Q-POC™ a revolutionary 30 minute PCR diagnostics device,...